DOCSLIB.ORG

List of Compound Classes Represented in the Wiley Registry 12 Database

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Wiley Registry® of Mass Spectral Data, 12th Edition Classification Index Wiley Registry® of Mass Spectral Data, 12th Edition Classification Index Classes Counts Benzene and substituted derivatives 24547 Fatty acid esters 11489 Naphthalenes 10532 Alkyl-phenylketones 9973 Stilbenes 9409 Anisoles 8839 Diphenylmethanes 8577 Aryl thioethers 8329 Ketals 8182 Alpha amino acid esters 6643 Nitrobenzenes 6501 Sesquiterpenoids 6452 Alpha amino acids and derivatives 6121 Bicyclic monoterpenoids 6108 Benzylethers 6084 Trialkylheterosilanes 5961 Phenylpropanes 5824 Styrenes 5549 Ketones 5401 Benzoic acid esters 5387 Phenylpyrazoles 5145 Benzenesulfonamides 4489 Phenol ethers 4384 Fatty alcohols 4192 Dimethoxybenzenes 4016 Biphenyls and derivatives 3846 Fatty acid methyl esters 3790 Phenylpyridines 3774 Benzyloxycarbonyls 3740 Triterpenoids 3581 Tetralins 3443 Dicarboxylic acids and derivatives 3429 Toluenes 3320 Chlorobenzenes 3289 Diterpenoids 3279 Carboxylic acid esters 3276 Phenylquinolines 3245 Phenanthrenes and derivatives 3234 Cyclic ketones 3173 Benzimidazoles 3148 Phenylphosphines and derivatives 3132 Quinazolines 3132 Cyclohexenones 3107 Alkylarylsilanes 3087 Oxanes 3085 Phenylpyrrolidines 3049 Aromatic monoterpenoids 3038 Gamma butyrolactones 3033 Heteroaromatic compounds 2978 Menthane monoterpenoids 2937 Anilides 2928 Tertiary alcohols 2912 Benzenoids 2876 Phenylpyrroles 2869 Pyridines and derivatives 2777 Benzenesulfonyl compounds 2763 Phenylmethylamines 2739 Anthracenes 2736 Benzofurans 2722 Benzodioxoles 2676 Carbazoles 2675 Dialkyl ethers 2582 Linear diarylheptanoids 2573 Branched unsaturated hydrocarbons 2558 Secondary alcohols 2509 Benzoyl derivatives 2483 Indoles 2472 Benzophenones 2399 Indoles and derivatives 2397 Benzanilides 2356 Dialkylarylamines 2314 Fluorenes 2273 Aryl-phenylketones 2262 Benzothiazoles 2237 Trifluoromethylbenzenes 2233 Aryl alkyl ketones 2217 Quinolines and derivatives 2211 Phenol esters 2171 Oxepanes 2148 Fluorobenzenes 2111 Phenylimidazoles 2072 Phenyl-1,2,4-triazoles 2071 3-alkylindoles 2064 Indanes 2061 Tetracarboxylic acids and derivatives 2051 Monoterpenoids 2043 Coumarins and derivatives 2021 Phthalimides 2017 Monocyclic monoterpenoids 1977 Quinoxalines 1972 N-acyl-alpha amino acids and derivatives 1959 Benzamides 1955 Metalloheterocyclic compounds 1950 Tetrahydrofurans 1905 Pyrimidones 1887 Tetrahydroisoquinolines 1882 Piperidines 1854 Aralkylamines 1844 Amphetamines and derivatives 1801 Aniline and substituted anilines 1800 Alpha amino acid amides 1785 Isoindolones 1782 Cinnamic acid esters 1781 Anthraquinones 1768 N,N-disubstituted p-toluenesulfonamides 1766 Linear 1,3-diarylpropanoids 1762 N-alkylindoles 1749 Benzoic acids and derivatives 1744 Alkyl aryl ethers 1695 Trialkylsilanes 1695 Nitriles 1683 Bromobenzenes 1676 Dialkyl alkylphosphonates 1675 Phenoxy compounds 1672 Tricarboxylic acids and derivatives 1670 Butenolides 1660 Naphthofurans 1652 Trialkylamines 1648 Benzenesulfonate esters 1642 Cyclohexanols 1625 Tosyl compounds 1615 1-benzopyrans 1614 Dichlorobenzenes 1590 Steroid esters 1551 Diphenylethers 1541 Terpene lactones 1538 Depsides and depsidones 1528 Phenyl-1,2,3-triazoles 1524 Aromatic anilides 1497 Hydroquinolones 1493 Naphthoquinones 1490 Diarylthioethers 1480 Naphthols and derivatives 1480 Cholesterols and derivatives 1478 Beta carbolines 1477 Polycyclic hydrocarbons 1473 Cyclic alcohols and derivatives 1451 Methoxyphenols 1446 Phenyl sulfoxides 1444 Phenylpiperidines 1437 Primary alcohols 1423 Methyl esters 1416 Phenylpiperazines 1405 Organochlorides 1387 Trimethylsilyl esters 1386 Beta amino acids and derivatives 1383 Lignans, neolignans and related compounds 1363 Benzazepines 1360 Phenylpyrimidines 1301 N-phenylureas 1260 N-acyl amines 1253 Monobactams 1242 Benzoxazines 1225 Acyclic monoterpenoids 1201 P-toluenesulfonamides 1195 Phenylpyrrolines 1193 Enones 1184 Diarylethers 1174 Triphenyl compounds 1164 Medium-chain fatty acids 1160 Indolecarboxylic acids and derivatives 1155 Phenylacetamides 1142 Beta-keto acids and derivatives 1140 Benzonitriles 1139 Fatty alcohol esters 1137 Benzylisoquinolines 1126 Chromones 1126 Androstane steroids 1117 Delta valerolactones 1112 Phenylhydrazines 1111 Barbituric acid derivatives 1109 Indanones 1102 O-glycosyl compounds 1099 Naphthalenecarboxylic acids 1084 Pyridinecarboxylic acids 1080 Cholestane steroids 1071 Organofluorides 1059 Indenes and isoindenes 1055 Xanthines 1053 Phenylnaphthalenes 1048 Androgens and derivatives 1041 1-benzothiophenes 1022 Nitrophenyl ethers 1019 Branched alkanes 1017 Indolines 1017 Acetals 1011 Pyrrolidines 1005 Pyranones and derivatives 1004 Morpholines 1002 N-benzylpiperidines 999 Pyrazines 999 2,2-dimethyl-1-benzopyrans 990 Phenyltetrazoles and derivatives 989 Naphthopyrans 987 Organobromides 985 Nitroaromatic compounds 982 Epoxides 978 Oxazolidinones 976 Pregnane steroids 973 Bipyridines and oligopyridines 967 Macrolides and analogues 967 Iridoids and derivatives 965 Phenylalkylamines 956 Nitrobenzoic acids and derivatives 955 Hydroquinolines 952 Methoxyanilines 948 Medium-chain aldehydes 947 Sulfanilides 941 1,3-dioxanes 939 Coumarans 939 Phenylalanine and derivatives 939 Acetanilides 932 Phenylcarbamic acid esters 931 Dithioketals 930 Isoquinolones and derivatives 928 1,4-benzodiazepines 926 Hydrophenanthrenes 923 Monosaccharides 891 Beta hydroxy acids and derivatives 890 Azulenes 859 Hippuric acids and derivatives 849 Retro-dihydrochalcones 848 Substituted pyrroles 847 Diterpene lactones 842 Methylpyridines 840 Harmala alkaloids 839 Phenothiazines 824 Indolecarboxylic acids 818 Phenyl-1,3-oxazoles 815 Pyrrole carboxylic acids and derivatives 807 Carbamate esters 800 Tertiary carboxylic acid amides 795 Phenanthridines and derivatives 792 Beta-diketones 791 Pyrans 787 2-phenylindoles 786 Benzothiazines 780 Long-chain fatty alcohols 777 Aminophenyl ethers 768 N-alkylpyrrolidines 763 Benzodiazepines 762 Unsaturated aliphatic hydrocarbons 760 1-hydroxy-4-unsubstituted benzenoids 758 Indolizidines 758 Azobenzenes 754 Isoquinolines and derivatives 750 Naphthyridines 748 Pyridopyrimidines 748 4-halobenzoic acids and derivatives 742 Estrane steroids 740 Azaspirodecane derivatives 739 Acylaminobenzoic acid and derivatives 734 Alkyldiarylamines 732 Cyclopropanecarboxylic acids and derivatives 719 Phenylimidazolidines 716 Xanthones 710 Retrochalcones 707 Cycloalkanes 703 2-benzopyrans 702 Morphinans 701 Gluco/mineralocorticoids, progestogins and derivatives 698 Organic transition metal salts 698 Acridines 676 Dithianes 676 Dihydropyranones 675 Phenylpyridazines 674 Dialkylamines 672 Vinyl chlorides 669 Cumenes 660 Enoate esters 657 Aryl ketones 640 C-nitro compounds 635 Triazolopyrimidines 629 Phenoxyacetic acid derivatives 627 Tetrahydropyridines 624 2-arylbenzofuran flavonoids 621 Oxosteroids 621 Steroids and steroid derivatives 604 Macrolactams 603 Alkanes 600 Polychlorinated biphenyls 600 Benzoxazoles 599 Aporphines 596 Porphyrins 596 Eudesmane, isoeudesmane or cycloeudesmane sesquiterpenoids 595 Thienopyrimidines 594 Bile acids, alcohols and derivatives 593 Pyrrolines 592 Thiophene carboxylic acids and derivatives 585 2,4-disubstituted thiazoles 582 1,3-dioxolanes 581 m-Xylenes 580 Benzotriazoles 575 Monoalkylamines 569 P-methoxybenzoic acids and derivatives 568 Xanthenes 568 Cinnamyl alcohols 564 Imidazopyridines 564 Carboxylic acids 563 Phenylbenzimidazoles 560 Indazoles 555 Pyrazoles 552 Piperidinones 549 P-benzoquinones 543 Kaurane diterpenoids 542 Nitronaphthalenes 541 Eudesmanolides, secoeudesmanolides, and derivatives 539 Aryl chlorides 538 Dialkylthioethers 538 Purines and purine derivatives 531 Tryptamines and derivatives 531 Prostaglandins and related compounds 527 Lactones 526 Pentacarboxylic acids and derivatives 526 Thienopyridines 522 1-hydroxy-2-unsubstituted benzenoids 521 Aryl-aldehydes 519 Organoheterocyclic compounds 519 Benzofuranones 518 Furofurans 518 2,4,5-trisubstituted thiazoles 517 Alkaloids and derivatives 516 Phosphonic acid diesters 516 2-halobenzoic acids and derivatives 514 Dihydropyridinecarboxylic acids and derivatives 513 Chloroquinolines 512 Gamma-keto acids and derivatives 512 Hydrocarbon derivatives 512 Phosphonic acid esters 508 Polyhalopyridines 505 Dibenzocycloheptenes 504 N-arylamides 504 Pyrrolidine carboxylic acids 504 Acetamides 502 Quinazolinamines 502 Trihalomethanes 501 Pyrrolopyridines 499 Triazoles 498 Aryltetralin lignans 495 Aminoquinolines and derivatives 490 2-heteroaryl carboxamides 489 C-glycosyl compounds 482 Coumaric acids and derivatives 482 N-phenylthioureas 481 Phenylhydantoins 481 Benzopyrans 479 Long-chain fatty acids 479 Phenylisoxazolidines 479 Phenylpropenes 477 Azepanes 476 Benzoic acids 475 Phenylpropanoic acids 475 Phenylbenzamines 473 o-Hydroxybenzoic acid esters 472 Organic metalloid salts 471 Phenanthrols 470 Secondary carboxylic acid amides 470 Piperidinecarboxylic acids 468 Dihydrofurans 467 Indanediones 464 Tetrapyrroles and derivatives 464 Halopyrimidines 463 Bi- and oligothiophenes 462 Aminopyridines and derivatives 461 Aminotoluenes 459 Aryl bromides 459 Pyridazines and derivatives 458 Benzyl alcohols 457 Peptides 457 Pyrimidines and pyrimidine derivatives 457 Alpha-hydrogen aldehydes 456 Nitrophenols 455 Iodobenzenes 451 Organic carbonic acids and derivatives 449 Sulfones 448 Dibenzazepines 447 Ketene acetals 447 1,3,5-triazine-2,4-diamines 446 2,5-disubstituted thiophenes 446 Indolyl carboxylic acids and derivatives 446 Azepines 443 Organooxygen compounds 442 Organoiodides 441 N-benzylbenzamides 440 N-acylpyrrolidines
Recommended publications
  • Neurotransmitter Resource Guide

    Neurotransmitter Resource Guide

    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
  • Discovery of Small Molecule and Peptide-Based Ligands for the Methyl-Lysine Binding Proteins 53Bp1 and Phf1/Phf19

    Discovery of Small Molecule and Peptide-Based Ligands for the Methyl-Lysine Binding Proteins 53Bp1 and Phf1/Phf19

    DISCOVERY OF SMALL MOLECULE AND PEPTIDE-BASED LIGANDS FOR THE METHYL-LYSINE BINDING PROTEINS 53BP1 AND PHF1/PHF19 Michael Thomas Perfetti A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Division of Chemical Biology and Medicinal Chemistry in the Doctoral Program of the UNC Eshelman School of Pharmacy. Chapel Hill 2015 Approved by: Stephen Frye David Lawrence Albert Bowers Brian Strahl Greg Gang Wang Andrew Lee © 2015 Michael Thomas Perfetti ALL RIGHTS RESERVED ii ABSTRACT Michael Thomas Perfetti: Discovery of Small Molecule and Peptide-based Ligands for the Methyl-Lysine Binding Proteins 53BP1 and PHF1/PHF19 (Under the direction of Stephen V. Frye) Improving the understanding of the role of chromatin regulators in the initiation, development, and suppression of cancer and other devastating diseases is critical, as they are integral players in the regulation of DNA integrity and gene expression. Developing chemical tools for histone binding proteins that possess cellular activity will allow for further elucidation of the specific function of this class of histone regulating proteins. This research specifically targeted two different classes of Tudor domain containing histone binding proteins that are directly involved in the DNA damage response and modulation of gene transcription activities. The first methyl-lysine binding protein targeted was 53BP1, which is a DNA damage response protein. 53BP1 uses a tandem tudor domain (TTD) to recognize histone H4 dimethylated on lysine 20 (H4K20me2), a post-translational modification (PTM) induced by double-strand DNA breaks.
  • THE BIOSYNTHESIS of SOME PHENOLIC ALKALOIDS a Thesis Submitted by GEOFFREY MELVILLE THOMAS for the Degree of DOCTOR of PHILOSOPH

    THE BIOSYNTHESIS of SOME PHENOLIC ALKALOIDS a Thesis Submitted by GEOFFREY MELVILLE THOMAS for the Degree of DOCTOR of PHILOSOPH

    /1 THE BIOSYNTHESIS OF SOME PHENOLIC ALKALOIDS a thesis submitted by GEOFFREY MELVILLE THOMAS for the degree of DOCTOR OF PHILOSOPHY of THE UNIVERSITY OF LONDON Imperial College, June 1963. London, S. W.7. ABSTRACT A brief review of the biosynthesis of alkaloids, other than those of the Amaryllidaceae and morphine groups, is given. The biosynthesis of these two groups is discussed more fully with particular reference to the evidence for the Barton and Cohen concept of phenol oxidation as a biogenetic mechanism. The incorporation of labelled phenolic precursors, derivatives of norbelladine, has been shown and by means of multiple labelled experiments incorporation as a whole, without degradation, has been proved. Other experiments described have thrown light on the earlier stages of biogenesis. The norlaudanosine derivative, (±) reticuline, has been shown to be incorporated into morphine, and an in vitro synthesis of thebaine from (±) reticuline using a radiochemical dilution method is de-scribed. I am deeply grateful to Professor D. H. R. Barton and Dr. G. W. Kirby for the privilege and pleasure of working under their supervision and for their great help in matters chemical and non-chemical. To the Salters Company I would like to express my sincere thanks for the award of a scholarship and for their interest during the tenure of it. My thanks are also due to Dr. D. W. Turner for advice on counting techniques, Mr. D. Aldrich and his staff for valuable technical assistance, Miss J. Cuckney for microanalyses, Mr. R.H. Young who grew the daffodils and poppies and to my many friends and co-workers at Imperial College.
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
  • Synthesis of Isothiocyanates Using DMT/NMM/Tso− As a New Desulfurization Reagent

    Synthesis of Isothiocyanates Using DMT/NMM/Tso− As a New Desulfurization Reagent

    molecules Article Synthesis of Isothiocyanates Using DMT/NMM/TsO− as a New Desulfurization Reagent Łukasz Janczewski 1,* , Dorota Kr˛egiel 2 and Beata Kolesi ´nska 1 1 Faculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland; [email protected] 2 Department of Environmental Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Wolczanska 171/173, 90-924 Lodz, Poland; [email protected] * Correspondence: [email protected] Abstract: Thirty-three alkyl and aryl isothiocyanates, as well as isothiocyanate derivatives from esters of coded amino acids and from esters of unnatural amino acids (6-aminocaproic, 4-(aminomethyl)benzoic, and tranexamic acids), were synthesized with satisfactory or very good yields (25–97%). Synthesis was performed in a “one-pot”, two-step procedure, in the presence of organic base (Et3N, DBU or NMM), and carbon disulfide via dithiocarbamates, with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium toluene-4-sulfonate (DMT/NMM/TsO−) as a desulfurization reagent. For the synthesis of aliphatic and aromatic isothiocyanates, reactions were carried out in a microwave reactor, and selected alkyl isothiocyanates were also synthesized in aqueous medium with high yields (72–96%). Isothiocyanate derivatives of L- and D-amino acid methyl esters were synthesized, under conditions without microwave radiation assistance, with low racemization (er 99 > 1), and their absolute configuration was confirmed by circular dichroism. Isothiocyanate derivatives of natural and unnatural amino acids were evaluated for antibacterial activity on E. coli and S. aureus bacterial strains, where the Citation: Janczewski, Ł.; Kr˛egiel,D.; most active was ITC 9e.
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting

    The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting

    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
  • Effect of Repeated MDMA Exposure on Rat Brain and Behaviour

    Effect of Repeated MDMA Exposure on Rat Brain and Behaviour

    Effect of repeated MDMA exposure on rat brain and behaviour by Ross van de Wetering A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Victoria University of Wellington, New Zealand 2020 Table of contents Absract ........................................................................................................................... 5 List of abbreviations ...................................................................................................... 7 CHAPTER 1: GENERAL INTRODUCTION ............................................................ 10 Introduction ........................................................................................................................ 10 Behavioural fundamentals of addiction ........................................................................... 12 Studying addiction ........................................................................................................... 13 Self-administration. ...................................................................................................... 14 Behavioural sensitisation. ............................................................................................ 18 Neurocircuitry of addiction ............................................................................................... 20 Ventral tegmental area and nucleus accumbens .............................................................. 20 Dopamine and reinforcement. .....................................................................................
  • Mrx CLINICAL ALERT

    Mrx CLINICAL ALERT

    MRx AUGUST 2018 CLINICAL ALERT YOUR MONTHLY SOURCE FOR DRUG INFORMATION HIGHLIGHTS HOT TOPIC: potential to placebo in non-dependent FIRST DRUG COMPRISED adult recreational drug users. EDITORIAL OF ACTIVE MARIJUANA DERIVATIVE APPROVED Cannabidiol oral solution was studied STAFF in 3 randomized, double-blind, placebo- Under Priority review, the United States controlled clinical trials including 516 (US) Food and Drug Administration (FDA) patients with either LGS or Dravet EDITOR IN CHIEF approved cannabidiol oral solution syndrome. Cannabidiol taken with ® Maryam Tabatabai (Epidiolex ) for the treatment of the patient’s current anticonvulsant PharmD seizures associated with Lennox-Gastaut regimen was shown to be effective syndrome (LGS) or Dravet syndrome in in reducing the frequency of seizures patients ≥ 2 years of age. It is the only when compared with placebo. Over EXECUTIVE EDITOR drug approved to treat Dravet syndrome the 12-week treatment period, the Carole Kerzic and the FDA designated it as an Orphan reduction in median number of LGS RPh drug and Rare pediatric disease drug seizures ranged from 37% to 44% with to treat both serious, difficult-to-treat CBD and 17% to 22% with placebo. DEPUTY EDITORS childhood seizure disorders. Dravet For Dravet syndrome, seizure reductions Stephanie Christofferson syndrome is diagnosed in approximately were 39% and 13% with CBD and PharmD 1 in 15,700 individuals in the US and placebo, respectively. Common side is characterized by frequent prolonged effects (≥ 10%) reported with CBD Jessica Czechowski seizures and developmental delays. LGS were increased liver transaminases PharmD involves frequent drop seizures and (particularly with concurrent use of impaired intellectual development.
  • Specificity of the Antibody Receptor Site to D-Lysergamide

    Specificity of the Antibody Receptor Site to D-Lysergamide

    Proc. Nat. Acad. Sci. USA Vol. 68, No. 7, pp. 1483-1487, July 1971 Specificity of the Antibody Receptor Site to D-Lysergamide: Model of a Physiological Receptor for Lysergic Acid Diethylamide (molecular structure/hallucinogenic/rabbit/guinea pig/psychotomimetic) HELEN VAN VUNAKIS, JOHN T. FARROW, HILDA B. GJIKA, AND LAWRENCE LEVINE Graduate Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02154 Commnunicated by Francis 0. Schmitt, April 21, 1971 ABSTRACT Antibodies to D-lysergic acid have been amine, and NN-dimethyl-3,4,5-trimethoxyphenylethylamine produced in rabbits and guinea pigs and a radioimmuno- were the generous gifts of Dr. W. E. Scott of Hoffmann-La assay for the hapten was developed. The specificity of this Iysergamide-antilysergamide reaction was determined by Roche. DOM (2,5-dimethoxy-4-methylamphetamine) was competitive binding with unlabeled lysergic acid diethyl- given to us by Dr. S. H. Snyder of Johns Hopkins Univer- amnide (LSD), psychotomimetic drugs, neurotransmitters, sity. Sandoz Pharmaceuticals provided us with ergonovine, and other compounds with diverse structures. LSD and methylergonovine, ergosine, and ergotomine. LSD tartarate several related ergot alkaloids were potent competitors, three to seven times more potent than lysergic acid itself. powder (Sandoz Batch no. 98601) and psilocybin powder The NN-dimethyl derivatives of several compounds, in- (Sandoz Batch no. 55001) were provided by the U.S. Food and cluding tryptamine, 5-hydroxytryptamine, 4-hydroxy- Drug Administration and the National Institute of Mental tryptamine, 5-methoxytryptamine, tyramine, and mesca- Health. line, were only about ten times less effective than lysergic Psilocin was obtained by dephosphorylating psilocybin acid, even though these compounds lack some of the ring systems of lysergic acid.
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No

    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No

    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
  • Neuropharmacology and Toxicology of Novel Amphetamine-Type Stimulants

    Neuropharmacology and Toxicology of Novel Amphetamine-Type Stimulants

    Neuropharmacology and toxicology of novel amphetamine-type stimulants Bjørnar den Hollander Institute of Biomedicine, Pharmacology University of Helsinki Academic Dissertation To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in lecture hall 2, Biomedicum Helsinki 1, Haartmaninkatu 8, on January 16th 2015 at 10 am. Helsinki 2015 Supervisors Thesis committee Esa R. Korpi, MD, PhD Eero Castrén, MD, PhD Institute of Biomedicine, Pharmacology Neuroscience Center Faculty of Medicine University of Helsinki P.O. Box 63 (Haartmaninkatu 8) P.O. Box 56 (Viikinkaari 4) 00014 University of Helsinki, Finland 00014 University of Helsinki, Finland Esko Kankuri, MD, PhD Sari Lauri, PhD Institute of Biomedicine, Pharmacology Neuroscience Center and Faculty of Medicine Department of Biosciences/ Physiology P.O. Box 63 (Haartmaninkatu 8) University of Helsinki 00014 University of Helsinki, Finland P.O.Box 65 (Viikinkaari 1) 00014 University of Helsinki, Finland Reviewers Dissertation opponent Atso Raasmaja, Professor, PhD Prof David Nutt DM FRCP FRCPsych Division of Pharmacology and FMedSci Pharmacotherapy Edmond J. Safra Chair of Faculty of Pharmacy Neuropsychopharmacology P. O. Box 56 (Viikinkaari 5E) Division of Brain Sciences 00014 University of Helsinki, Finland Dept of Medicine Imperial College London Petri J. Vainio, MD, PhD Burlington Danes Building Pharmacology, Drug Development and Hammersmith Hospital Therapeutics Du Cane Road Institute of Biomedicine London W12 0NN, United Kingdom Faculty of Medicine Kiinamyllynkatu 10 C 20014 University of Turku, Finland The cover layout is done by Anita Tienhaara. The cover photo is by Edd Westmacott and shows a close-up of ecstasy tablets, photographed in Amsterdam in 2004.